Limited protective effect of the CCR5δ32/CCR5δ32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus

Journal of Infectious Diseases

Volumn 187, Issue 2, 2003, Pages 215-225

  Iversen, Astrid K N ^a,c,i   Christiansen, Claus Bohn ^d   Attermann, Jørn ^a   Eugen Olsen, Jesper ^e   Schulman, Sam ^f   Berntorp, Erik ^g   Ingerslev, Jørgen ^b   Fugger, Lars ^b   Scheibel, Elma ^c   Tengborn, Lillian ^h   Gerstoft, Jan ^c   Dickmeiss, Ebbe ^c   Svejgaard, Arne ^c   Skinhøj, Peter ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d STATENS SERUM INSTITUT   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; TUCARESOL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DISEASE COURSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SURVIVAL RATE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGING; AMINO ACID SEQUENCE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEMOPHILIA A; HEMOPHILIA B; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; RISK FACTORS; SURVIVAL RATE;

EID: 0037439281     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345881     Document Type: Article

References (65)

1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
2. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996;35:3362-7.
3. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
4. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381:661-6.
5. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-63.
6. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity, develop during the asymptomatic stage before disease progression. J Virol 1994;68:4400-8.
7. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
8. Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, Cullen BR. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 2001;75:6776-85.
9. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58.
10. Ross TM, Cullen BR. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop. Proc Natl Acad Sci USA 1998;95:7682-6.
11. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-64.
12. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66:6777-80.
13. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-7.
14. Chesebro B, Wehrly K, Nishio J, Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-54.
15. Milich L, Margolin B, Swanstrom R. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol 1993;67:5623-34.
16. Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J Virol 1996;70:9055-9.
17. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62.
18. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
19. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-I infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5.
20. Balotta C, Bagnarelli P, Violin M, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997;11:F67-71.
21. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997;349:1219.
22. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol 1998;72:6040-7.
23. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997;349:1219-20.
24. Heiken H, Becker S, Bastisch I, Schmidt RE. HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32. AIDS 1999;13:529-30.
25. Biti R, French R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997;3:252-3.
26. Kuipers H, Workman C, Dyer W, Geczy A, Sullivan J, Oelrichs R. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3′A allele. AIDS 1999;13:433-4.
27. Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-delta32/delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002;29:307-13.
28. Lucotte G, Mercier G. Distribution of the CCR5 gene 32-bp deletion in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:174-7.
29. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-10.
30. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996;2:1240-3.
31. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681-91.
32. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998;282:1907-11.
33. Lee B, Doranz BJ, Rana S, et al. Influence of the CCR2-V641 polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998;72:7450-8.
34. Ahlfors K. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis 1984;16:335-7.
35. Kryger P, Gerstoft J, Pedersen NS, Nielsen JO. Increased prevalence of cytomegalovirus antibodies in homosexual men with syphilis: relation to sexual behaviour. Scand J Infect Dis 1984;16:381-4.
36. Rucker J, Edinger AL, Sharron M, et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997;71:8999-9007.
37. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 1997;276:1874-8.
38. Pleskoff O, Treboute C, Alizon M. The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins. J Virol 1998;72:6389-97.
39. Ohagen A, Li L, Rosenzweig A, Gabuzda D. Cell-dependent mechanisms restrict the HIV type 1 coreceptor activity of US28, a chemokine receptor homolog encoded by human cytomegalovirus. AIDS Res Hum Retroviruses 2000;16:27-35.
40. Webster A, Lee CA, Cook DG, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet 1989;2:63-6.
41. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect 1995;114:361-72.
42. Sabin CA, Devereux HL, Clewley G, et al. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. J Infect Dis 2000;181:1800-3.
43. Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 1999;341:77-84.
44. Bowen EF, Wilson P, Cope A, et al. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 1996;10:1515-20.
45. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999;73:7027-30.
46. Detels R, Leach CT, Hennessey K, et al. Persistent cytomegalovirus infection of semen increases risk of AIDS. J Infect Dis 1994;169:766-8.
47. Becherer PR, Smiley ML, Matthews TJ, Weinhold KJ, McMillan CW, White GC 2nd. Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hematol 1990;34:204-9.
48. Rabkin CS, Hatzakis A, Griffiths PD, et al. Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. National Cancer Institute Multicenter Hemophilia Cohort Study Group. J Infect Dis 1993;168:1260-3.
49. Touloumi G, Karafoulidou A, Gialeraki A, et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:89-97.
50. Ryder LP, Andersen E, Svejgaard A. An HLA map of Europe. Hum Hered 1978;28:171-200.
51. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987;36(Suppl 1):1S-15S.
52. Kuiken CL, Foley B, Hahn B, et al., eds. Human retroviruses and AIDS 2001: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory, 2001.
53. Croce F, Citterio P, Bulgheroni E, et al. Analysis of the viral tropism of isolates obtained from patients with HIV-1 infection treated with tucaresol: a compilation and analysis of nucleic acid and amino acid sequences (entry AF451381 and AF4513828). Hum Retroviruses and AIDS 2001.
54. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1887-95.
55. Rusconi S, La Seta Catamancio S, Citterio P, et al. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J Virol 2000;74:9328-32.
56. Rhodes J, Chen H, Hall SR, et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature 1995;377:71-5.
57. Chen H, Rhodes J. Schiff base forming drugs: mechanisms of immune potentiation and therapeutic potential. J Mol Med 1996;74:497-504.
58. Chen H, Hall S, Heffernan B, Thompson NT, Rogers MV, Rhodes J. Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2. J Immunol 1997;159:2274-81.
59. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H. No evidence for an effect of the CCR5 Δ32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injection drug users. J Infect Dis 1999;179:825-31.
60. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-65.
61. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation. Lancet 1996;347:1573-9.
62. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative reanalysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on Sero-Conversion to AIDS and Death in Europe. Lancet 2000;355:1131-7.
63. Amara A, Gall SL, Schwartz O, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997;186:139-46.
64. Reynes J, Portales P, Segondy M, et al. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 2001;15:1627-34.
65. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 35 1125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-23.